BOOK
Head and Neck Cancer, An Issue of Hematology/Oncology Clinics of North America, E-Book
(2016)
Additional Information
Book Details
Abstract
This issue of Hematology/Oncology Clinics of North America is devoted to Head and Neck Cancer. Guest Editor Alexander Colevas, MD has assembled a group of expert authors to review the following topics: Epidemiology of SCCHN; Genetics of Head and Neck Cancers; Molecular Biology of Head and Neck Cancers; Quality of Life in Head and Neck Cancer Treatment; Nasopharyngeal Carcinoma; Evolving Surgical Techniques in SCCHN; Radiation Oncology New Approaches in SCCHN; Thyroid Gland Malignancies; Sequential and Concurrent Chemoradiation; Systemic Chemotherapy for SCCHN Focus on New targets and Agents; EGFR Inhibition in SCCHN; Diagnostic and Therapeutic Assessment Imaging in Head and Neck Cancer; Salivary Gland Cancers; Immunotherapy in SCCHN; Human Papillomavirus in SCCHN; and Supportive Care Issues in SCCHN Treatment and Survivorship: Dental, Nutrition, Speech and Swallowing, Depression.
Table of Contents
| Section Title | Page | Action | Price |
|---|---|---|---|
| Front Cover | Cover | ||
| Head and Neck Cancer\r | i | ||
| Copyright\r | ii | ||
| Contributors | iii | ||
| CONSULTING EDITORS | iii | ||
| EDITOR | iii | ||
| AUTHORS | iii | ||
| Contents | vii | ||
| Preface: New Diseases and New Treatments—Head and Neck Cancer Updates\r | vii | ||
| Molecular Aspects of Head and Neck Cancer Therapy\r | vii | ||
| Novel Targeted Agents in Head and Neck Squamous Cell Carcinoma\r | vii | ||
| Epidermal Growth Factor Receptor Inhibition in Squamous Cell Carcinoma of the Head and Neck\r | vii | ||
| Immunotherapy for Head and Neck Squamous Cell Carcinoma\r | viii | ||
| Anticipation of the Impact of Human Papillomavirus on Clinical Decision Making for the Head and Neck Cancer Patient\r | viii | ||
| Sequential and Concurrent Chemoradiation: State of the Art\r | viii | ||
| Transoral Endoscopic Head and Neck Surgery: The Contemporary Treatment of Head and Neck Cancer\r | viii | ||
| Radiation Oncology—New Approaches in Squamous Cell Cancer of the Head and Neck\r | ix | ||
| Chemotherapy for Nasopharyngeal Carcinoma – Current Recommendation and Controversies\r | ix | ||
| Thyroid Gland Malignancies\r | ix | ||
| Salivary Gland Malignancies\r | x | ||
| Supportive Care and Survivorship Strategies in Management of Squamous Cell Carcinoma of the Head and Neck\r | x | ||
| HEMATOLOGY/ONCOLOGY\rCLINICS OF NORTH AMERICA\r | xi | ||
| FORTHCOMING ISSUES | xi | ||
| February 2016 | xi | ||
| April 2016 | xi | ||
| June 2016 | xi | ||
| RECENT ISSUES | xi | ||
| October 2015 | xi | ||
| August 2015 | xi | ||
| June 2015 | xi | ||
| Preface: New Diseases and New Treatments—Head and Neck Cancer Updates \r | xiii | ||
| Molecular Aspects of Head and Neck Cancer Therapy | 971 | ||
| Key points | 971 | ||
| INTRODUCTION | 971 | ||
| TUMOR SUPPRESSORS FREQUENTLY DRIVE HEAD AND NECK SQUAMOUS CELL CARCINOMA BUT ARE DIFFICULT TO TARGET | 973 | ||
| ONCOGENE MUTATIONS ARE UNCOMMON IN HEAD AND NECK SQUAMOUS CELL CARCINOMA WITH LIMITED POTENTIAL FOR TARGETED THERAPY IN SPE ... | 978 | ||
| HUMAN PAPILLOMA VIRUS INFECTION AND INTEGRATION ALTERS TUMOR BIOLOGY AND TRIGGERS CARCINOGENESIS BY DIVERGENT BIOLOGIC MECH ... | 979 | ||
| INTRATUMOR HETEROGENEITY POSES UNIQUE THERAPEUTIC CHALLENGES AND OPPORTUNITIES IN HEAD AND NECK SQUAMOUS CELL CARCINOMA | 980 | ||
| ADDITIONAL FRONTIERS IN HEAD AND NECK SQUAMOUS CELL CARCINOMA DIAGNOSTICS AND THERAPEUTICS | 982 | ||
| Biomarkers Remain Elusive but Are Worthy of Pursuit | 982 | ||
| MicroRNAs in Head and Neck Squamous Cell Carcinoma Offer an Additional, Poorly Understood Layer of Regulation in Tumor Biology | 983 | ||
| Networking Analyses Can Identify Transcriptional and Regulatory Cassettes | 984 | ||
| Epigenetic Changes and Histone Modification May Enable Tumor Resistance | 985 | ||
| Tumor-Immune Interactions and Immunotherapy Offer Novel Methods for Cancer Surveillance | 985 | ||
| A Darwinian View of Head and Neck Oncology Offers Creative Perspectives into Cancer Biology and Treatment | 986 | ||
| SUMMARY | 986 | ||
| REFERENCES | 987 | ||
| Novel Targeted Agents in Head and Neck Squamous Cell Carcinoma | 993 | ||
| Key points | 993 | ||
| INTRODUCTION | 993 | ||
| DNA DAMAGE RESPONSE AND CELL CYCLE REGULATION TARGETED AGENTS | 994 | ||
| Targeting Dysfunctional p53 | 994 | ||
| Targeting Cyclin-Dependent Kinases | 995 | ||
| Targeting Poly-ADP Ribose Polymerase | 996 | ||
| PI3K-MTOR TARGETED AGENTS | 996 | ||
| NOTCH PATHWAY TARGETED AGENTS | 997 | ||
| TRANSMEMBRANE GROWTH FACTOR RECEPTOR TARGETED AGENTS | 999 | ||
| c-MET Receptor | 999 | ||
| Fibroblast Growth Factor Receptors | 999 | ||
| Axl | 1000 | ||
| ANGIOGENESIS TARGETED AGENTS | 1000 | ||
| SUMMARY | 1004 | ||
| REFERENCES | 1004 | ||
| Epidermal Growth Factor Receptor Inhibition in Squamous Cell Carcinoma of the Head and Neck | 1011 | ||
| Key points | 1011 | ||
| THE EPIDERMAL GROWTH FACTOR RECEPTOR | 1011 | ||
| INHIBITION OF EPIDERMAL GROWTH FACTOR RECEPTOR | 1013 | ||
| Anti-Epidermal Growth Factor Receptor Monoclonal Antibodies | 1013 | ||
| The role of anti-epidermal growth factor receptor monoclonal antibodies in the multimodal curative treatment | 1013 | ||
| Radiotherapy plus anti-epidermal growth factor receptor monoclonal antibodies versus radiotherapy | 1013 | ||
| Radiotherapy plus anti-epidermal growth factor receptor monoclonal antibodies versus chemoradiation | 1014 | ||
| Anti-epidermal growth factor receptor monoclonal antibodies and concurrent radiotherapy after induction chemotherapy | 1018 | ||
| Chemoradiation versus chemoradiation plus anti-epidermal growth factor receptor monoclonal antibodies | 1018 | ||
| Anti-epidermal growth factor receptor monoclonal antibodies as adjuvant therapy | 1019 | ||
| The role of anti-epidermal growth factor receptor monoclonal antibodies in recurrent and/or metastatic disease | 1019 | ||
| First-line treatment in combination with platinum-based chemotherapy | 1019 | ||
| Second-line treatment after platinum-based chemotherapy | 1020 | ||
| Other anti-epidermal growth factor receptor monoclonal antibodies with preliminary results | 1021 | ||
| Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors | 1021 | ||
| The role of anti-epidermal growth factor receptor tyrosine kinase inhibitors in multimodal curative treatment | 1021 | ||
| The role of anti-epidermal growth factor receptor tyrosine kinase inhibitors in recurrent and/or metastatic disease | 1021 | ||
| STRATEGIES TO OVERCOME RESISTANCE TO ANTI-EPIDERMAL GROWTH FACTOR RECEPTOR THERAPY | 1023 | ||
| Blockage of Multiple Human Epidermal Receptors | 1023 | ||
| Background | 1023 | ||
| The role of human epidermal receptor inhibitors in the multimodal curative treatment | 1023 | ||
| The role of human epidermal receptor inhibitors in recurrent and/or metastatic disease | 1024 | ||
| Dual Targeting Monoclonal Antibodies or Mixture of Monoclonal Antibodies | 1024 | ||
| SUMMARY | 1028 | ||
| REFERENCES | 1028 | ||
| Immunotherapy for Head and Neck Squamous Cell Carcinoma | 1033 | ||
| Key points | 1033 | ||
| INTRODUCTION | 1033 | ||
| IMMUNE CHECKPOINT BLOCKADE | 1034 | ||
| AUGMENTING CETUXIMAB-BASED IMMUNOTHERAPY | 1036 | ||
| VACCINES | 1037 | ||
| ENGINEERED T CELLS | 1039 | ||
| SUMMARY | 1040 | ||
| REFERENCES | 1040 | ||
| Anticipation of the Impact of Human Papillomavirus on Clinical Decision Making for the Head and Neck Cancer Patient | 1045 | ||
| Key points | 1045 | ||
| INTRODUCTION | 1045 | ||
| HUMAN PAPILLOMAVIRUS BIOLOGY | 1046 | ||
| EPIDEMIOLOGY OF HUMAN PAPILLOMAVIRUS–POSITIVE OROPHARYNGEAL CANCER | 1047 | ||
| Tumor Human Papillomavirus Status and Disease: Survival and Overall Survival | 1048 | ||
| Molecular Mechanisms, Human Papillomavirus Status, and Prognosis | 1048 | ||
| HUMAN PAPILLOMAVIRUS TUMOR STATUS, RACE, AND SURVIVAL | 1049 | ||
| HUMAN PAPILLOMAVIRUS STATUS, TUMOR STAGING, AND PROGNOSIS | 1051 | ||
| HUMAN PAPILLOMAVIRUS STATUS, SURGICAL RESECTION, EXTRACAPSULAR EXTENSION, AND RISK OF CANCER PROGRESSION | 1051 | ||
| TUMOR HUMAN PAPILLOMAVIRUS STATUS AND OVERALL SURVIVAL POSTPROGRESSION | 1052 | ||
| HUMAN PAPILLOMAVIRUS STATUS AND CLINICAL TRIAL DESIGN | 1053 | ||
| REFERENCES | 1054 | ||
| Sequential and Concurrent Chemoradiation | 1061 | ||
| Key points | 1061 | ||
| INTRODUCTION | 1061 | ||
| SUMMARY OF RECENT RANDOMIZED CLINICAL TRIALS COMPARING SEQUENTIAL CHEMORADIOTHERAPY VERSUS CONCURRENT CHEMORADIOTHERAPY | 1062 | ||
| LARYNX PRESERVATION RANDOMIZED TRIALS: SEQUENTIAL CHEMORADIOTHERAPY VERSUS CONCURRENT CHEMORADIOTHERAPY | 1066 | ||
| CLOSING THE CONTROVERSY: ONGOING RANDOMIZED PHASE III TRIALS OF SEQUENTIAL CHEMORADIOTHERAPY VERSUS CONCURRENT CHEMORADIOTH ... | 1067 | ||
| PATIENT SELECTION AND RISK STRATIFICATION IN LOCALLY ADVANCED HEAD AND NECK CANCER: ONE SIZE DOES NOT FIT ALL | 1068 | ||
| STATE OF THE ART: FUTURE DIRECTIONS | 1068 | ||
| Deintensification Strategies for Low-risk Locally Advanced Head and Neck Cancer | 1068 | ||
| Intensification Strategies for High-risk Locally Advanced Head and Neck Cancer | 1069 | ||
| SUMMARY | 1072 | ||
| REFERENCES | 1072 | ||
| Transoral Endoscopic Head and Neck Surgery | 1075 | ||
| Key points | 1075 | ||
| BACKGROUND AND INTRODUCTION | 1075 | ||
| The Multidisciplinary Care of Head and Neck Cancer | 1075 | ||
| TRANSORAL ENDOSCOPIC HEAD AND NECK SURGERY | 1077 | ||
| Role of Endoscopic Head and Neck Surgery in Oropharyngeal Cancer | 1079 | ||
| Role of Endoscopic Head and Neck Surgery in Laryngeal Cancer | 1080 | ||
| Role of Endoscopic Head and Neck Surgery in Hypopharyngeal Cancer | 1080 | ||
| ONCOLOGIC OUTCOMES OF ENDOSCOPIC HEAD AND NECK SURGERY | 1080 | ||
| Endoscopic Head and Neck Surgery Outcomes for Oropharyngeal Cancer | 1081 | ||
| Endoscopic Head and Neck Surgery Outcomes for Laryngeal Cancer | 1081 | ||
| Endoscopic Head and Neck Surgery Outcomes for Hypopharyngeal Cancer | 1084 | ||
| FUNCTIONAL OUTCOMES OF ENDOSCOPIC HEAD AND NECK SURGERY | 1084 | ||
| ROLE OF ENDOSCOPIC HEAD AND NECK SURGERY IN RECURRENT OROPHARYNGEAL CANCER | 1085 | ||
| FUTURE PERSPECTIVE AND SUMMARY | 1085 | ||
| REFERENCES | 1087 | ||
| Radiation Oncology—New Approaches in Squamous Cell Cancer of the Head and Neck | 1093 | ||
| Key points | 1093 | ||
| INTRODUCTION | 1093 | ||
| Overview | 1094 | ||
| IMAGING ADVANCES | 1094 | ||
| Computed Tomography Scans | 1095 | ||
| PET, PET–Computed Tomography Imaging | 1095 | ||
| MRI Imaging | 1095 | ||
| ADVANCES IN RADIATION DELIVERY | 1097 | ||
| Image Guidance | 1097 | ||
| Adaptive Replanning | 1097 | ||
| Alternative Photon Delivery | 1098 | ||
| Helical Tomotherapy | 1098 | ||
| Proton Therapy | 1099 | ||
| Clinical Experience | 1099 | ||
| Sinonasal malignancies | 1099 | ||
| Nasopharyngeal cancer | 1099 | ||
| Oropharyngeal cancer | 1099 | ||
| Intensity Modulated Proton Therapy | 1099 | ||
| CLINICALLY BASED ADVANCES | 1100 | ||
| SUMMARY | 1101 | ||
| REFERENCES | 1101 | ||
| Chemotherapy for Nasopharyngeal Carcinoma – Current Recommendation and Controversies | 1107 | ||
| Key points | 1107 | ||
| INTRODUCTION | 1108 | ||
| BACKGROUND FOR THE CURRENT GUIDELINES | 1108 | ||
| CURRENT INTERNATIONAL GUIDELINES | 1109 | ||
| UNANSWERED QUESTIONS AND RECENT STUDIES | 1109 | ||
| Is Chemotherapy Necessary for All Stage II? | 1109 | ||
| Which Is the Best Treatment of Stage III–IVB? | 1110 | ||
| Concurrent versus concurrent-adjuvant chemoradiotherapy | 1110 | ||
| Concurrent versus induction-concurrent chemoradiotherapy | 1113 | ||
| Concurrent-adjuvant versus induction-concurrent chemoradiotherapy | 1114 | ||
| Can the Current Regimen Be Replaced by More Potent and/or Less Toxic Drugs? | 1115 | ||
| Replacing cisplatin with other platinum | 1115 | ||
| Replacing fluorouracil with other drugs | 1115 | ||
| The value of taxanes and gemcitabine combination | 1116 | ||
| What Is the Implication on the Use of Chemotherapy by Modern Radiotherapy Technique? | 1116 | ||
| SUMMARY | 1117 | ||
| REFERENCES | 1117 | ||
| Thyroid Gland Malignancies | 1123 | ||
| Key points | 1123 | ||
| INTRODUCTION | 1124 | ||
| GENETICS OF THYROID CANCER | 1125 | ||
| Baseline Evaluation | 1127 | ||
| Primary Treatment | 1127 | ||
| Long-term Surveillance | 1132 | ||
| NONPHARMACOLOGIC THERAPY | 1135 | ||
| External Beam Radiation | 1135 | ||
| Localized Therapies | 1135 | ||
| PHARMACOLOGIC THERAPIES | 1137 | ||
| Bone-modulating Drugs | 1137 | ||
| Kinase Inhibitors | 1137 | ||
| SUMMARY | 1140 | ||
| REFERENCES | 1140 | ||
| Salivary Gland Malignancies | 1145 | ||
| Key points | 1145 | ||
| INTRODUCTION | 1145 | ||
| INITIAL EVALUATION | 1146 | ||
| SURGICAL MANAGEMENT | 1146 | ||
| Surgery of the Parotid Gland and Management of the Facial Nerve | 1146 | ||
| Surgery of the Submandibular and Sublingual Glands | 1147 | ||
| Management of the Neck | 1148 | ||
| RADIATION THERAPY | 1148 | ||
| Neutron Radiotherapy | 1148 | ||
| SYSTEMIC THERAPY | 1149 | ||
| The Role of Conventional Chemotherapy | 1150 | ||
| Studies of Target Agents | 1151 | ||
| ONGOING RESEARCH AND FUTURE DIRECTIONS | 1152 | ||
| Locally Advanced Disease | 1152 | ||
| Recurrent/Metastatic Disease | 1152 | ||
| REFERENCES | 1153 | ||
| Supportive Care and Survivorship Strategies in Management of Squamous Cell Carcinoma of the Head and Neck | 1159 | ||
| Key points | 1159 | ||
| INTRODUCTION | 1159 | ||
| SURVIVORSHIP CARE PLANS | 1160 | ||
| CANCER TREATMENT–RELATED PHYSICAL EFFECTS | 1161 | ||
| CANCER-RELATED PSYCHOLOGICAL DISTRESS | 1162 | ||
| SUBSTANCE ABUSE AND SURVIVORSHIP | 1163 | ||
| ONCOLOGIC SURVEILLANCE AND DETECTION OF SECOND PRIMARY MALIGNANCIES | 1163 | ||
| SUMMARY | 1164 | ||
| REFERENCES | 1164 | ||
| Index | 1169 |